Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Hana M. El Sahly(Baylor College of Medicine), Jacqueline M. Miller(Moderna Therapeutics (United States)), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Gregory Feldman, Susanne Doblecki‐Lewis(University of Maryland, Baltimore), Lisa A. Jackson(Kaiser Permanente Washington Health Research Institute), Barney S. Graham(National Institutes of Health), Thomas Campbell(University of Colorado Anschutz Medical Campus), Rolando Pajón(Moderna Therapeutics (United States)), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deb Manzo(University of Maryland, Baltimore), Heather Clouting(University of Maryland, Baltimore), Marcus Zervos(Henry Ford Health System), Holly Janes(Fred Hutch Cancer Center), Kathleen M. Neuzil(Center for Global Development), Michael Levin(University of Cape Town), Dean Follmann(National Institute of Allergy and Infectious Diseases), Lawrence Corey(Fred Hutch Cancer Center), Allison August(University of Maryland, Baltimore), Jesse L. Clark(University of Maryland, Baltimore), Brett Leav(University of Maryland, Baltimore), John R. Mascola(National Institute of Allergy and Infectious Diseases), Judith M. Martin(University of Maryland, Baltimore), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Evan J. Anderson(Emory University), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), F. Schödel(St. Marianna University School of Medicine), Mary Marovich(University of Maryland, Baltimore), Lindsey R. Baden(Brigham and Women's Hospital), Shu Han(Sichuan University), C Kennelly(Target (United States)), Bruce Rankin(University of Maryland, Baltimore), Frank Eder(University of Maryland, Baltimore), Laura Polakowski(University of Maryland, Baltimore), Weiping Deng(Yunnan Agricultural University), Brandon Essink(Velocity Clinical Research (United States)), Laurie J. Han-Conrad(University of Maryland, Baltimore)
Cited by 661
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k